349 related articles for article (PubMed ID: 32004442)
1. EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition.
Karakashev S; Fukumoto T; Zhao B; Lin J; Wu S; Fatkhutdinov N; Park PH; Semenova G; Jean S; Cadungog MG; Borowsky ME; Kossenkov AV; Liu Q; Zhang R
Cancer Cell; 2020 Feb; 37(2):157-167.e6. PubMed ID: 32004442
[TBL] [Abstract][Full Text] [Related]
2. Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors.
Karakashev S; Zhang R
Mol Cell Oncol; 2020; 7(4):1760675. PubMed ID: 32944622
[TBL] [Abstract][Full Text] [Related]
3. Opening a Door to PARP Inhibitor-Induced Lethality in HR-Proficient Human Tumor Cells.
Hatchi E; Livingston DM
Cancer Cell; 2020 Feb; 37(2):139-140. PubMed ID: 32049041
[TBL] [Abstract][Full Text] [Related]
4. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
Dev H; Chiang TW; Lescale C; de Krijger I; Martin AG; Pilger D; Coates J; Sczaniecka-Clift M; Wei W; Ostermaier M; Herzog M; Lam J; Shea A; Demir M; Wu Q; Yang F; Fu B; Lai Z; Balmus G; Belotserkovskaya R; Serra V; O'Connor MJ; Bruna A; Beli P; Pellegrini L; Caldas C; Deriano L; Jacobs JJL; Galanty Y; Jackson SP
Nat Cell Biol; 2018 Aug; 20(8):954-965. PubMed ID: 30022119
[TBL] [Abstract][Full Text] [Related]
5. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
Talens F; Jalving M; Gietema JA; Van Vugt MA
Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
[TBL] [Abstract][Full Text] [Related]
7. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
8. SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair.
Lin S; Tian J; He Q; Yang M; Chen Z; Belogurov AA; Li X; Zhang F; Liu Y; Chen G
Dis Markers; 2022; 2022():7243146. PubMed ID: 36267463
[TBL] [Abstract][Full Text] [Related]
9. Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers.
Reilly NM; Yard BD; Pittman DL
Methods Mol Biol; 2019; 1999():3-29. PubMed ID: 31127567
[TBL] [Abstract][Full Text] [Related]
10. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
[TBL] [Abstract][Full Text] [Related]
11. CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity.
Karakashev S; Zhu H; Wu S; Yokoyama Y; Bitler BG; Park PH; Lee JH; Kossenkov AV; Gaonkar KS; Yan H; Drapkin R; Conejo-Garcia JR; Speicher DW; Ordog T; Zhang R
Nat Commun; 2018 Feb; 9(1):631. PubMed ID: 29434212
[TBL] [Abstract][Full Text] [Related]
12. Functional inhibition of RECQL5 helicase elicits non-homologous end joining response and sensitivity of breast cancers to PARP inhibitor.
Philip KT; Dutta K; Chakraborty S; Patro BS
Int J Biochem Cell Biol; 2023 Aug; 161():106443. PubMed ID: 37392863
[TBL] [Abstract][Full Text] [Related]
13. LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination-mediated DNA double strand break repair.
Chen L; Hou J; Zeng X; Guo Q; Deng M; Kloeber JA; Tu X; Zhao F; Wu Z; Huang J; Luo K; Kim W; Lou Z
Clin Transl Med; 2021 Mar; 11(3):e341. PubMed ID: 33784003
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermia synergistically enhances antitumor efficacy of PARP inhibitor through impacting homologous recombination repair and oxidative stress in vitro.
Wu Q; Wei M; Yao L; Cheng X; Lu W; Xie X; Li X
Biochem Biophys Res Commun; 2022 Sep; 619():49-55. PubMed ID: 35738064
[TBL] [Abstract][Full Text] [Related]
15. CHAMP1 binds to REV7/FANCV and promotes homologous recombination repair.
Li F; Sarangi P; Iyer DR; Feng H; Moreau L; Nguyen H; Clairmont C; D'Andrea AD
Cell Rep; 2022 Aug; 40(9):111297. PubMed ID: 36044844
[TBL] [Abstract][Full Text] [Related]
16. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
17. PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks.
Metzger MJ; Stoddard BL; Monnat RJ
DNA Repair (Amst); 2013 Jul; 12(7):529-34. PubMed ID: 23684799
[TBL] [Abstract][Full Text] [Related]
18. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.
Ceccaldi R; Liu JC; Amunugama R; Hajdu I; Primack B; Petalcorin MI; O'Connor KW; Konstantinopoulos PA; Elledge SJ; Boulton SJ; Yusufzai T; D'Andrea AD
Nature; 2015 Feb; 518(7538):258-62. PubMed ID: 25642963
[TBL] [Abstract][Full Text] [Related]
19. CHAMP1-POGZ counteracts the inhibitory effect of 53BP1 on homologous recombination and affects PARP inhibitor resistance.
Fujita H; Ikeda M; Ui A; Ouchi Y; Mikami Y; Kanno SI; Yasui A; Tanaka K
Oncogene; 2022 May; 41(19):2706-2718. PubMed ID: 35393543
[TBL] [Abstract][Full Text] [Related]
20. The dystonia gene THAP1 controls DNA double-strand break repair choice.
Shinoda K; Zong D; Callen E; Wu W; Dumitrache LC; Belinky F; Chari R; Wong N; Ishikawa M; Stanlie A; Multhaupt-Buell T; Sharma N; Ozelius L; Ehrlich M; McKinnon PJ; Nussenzweig A
Mol Cell; 2021 Jun; 81(12):2611-2624.e10. PubMed ID: 33857404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]